Impact of Thiopurine Exposure on Immunogenicity to Infliximab Is Negligible in the Setting of Elevated Infliximab Concentrations.
作者信息
Ungaro Ryan C, Colombel Jean-Frederic, Dubinsky Marla C, Jain Anjali, Dervieux Thierry
机构信息
Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Prometheus Laboratories, San Diego, CA, USA.
出版信息
Inflamm Bowel Dis. 2022 Mar 30;28(4):649-651. doi: 10.1093/ibd/izab232.
Abstract
摘要
相似文献
1
Impact of Thiopurine Exposure on Immunogenicity to Infliximab Is Negligible in the Setting of Elevated Infliximab Concentrations.在英夫利昔单抗浓度升高的情况下，硫嘌呤暴露对英夫利昔单抗免疫原性的影响可忽略不计。
Inflamm Bowel Dis. 2022 Mar 30;28(4):649-651. doi: 10.1093/ibd/izab232.
2
Thiopurine Metabolism in the Era of Combotherapy.联合治疗时代的硫嘌呤代谢
Inflamm Bowel Dis. 2016 Jun;22(6):1496-501. doi: 10.1097/MIB.0000000000000737.
3
External Validation of a Thiopurine Monitoring Algorithm on the SONIC Clinical Trial Dataset.基于SONIC临床试验数据集的硫嘌呤监测算法的外部验证
Clin Gastroenterol Hepatol. 2018 Mar;16(3):449-451. doi: 10.1016/j.cgh.2017.08.021. Epub 2017 Aug 22.
4
Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.先前接受过英夫利昔单抗治疗的炎症性肠病患者中硫嘌呤代谢物、阿达木单抗和针对阿达木单抗的抗体之间的相互作用。
Dig Dis Sci. 2018 Jun;63(6):1583-1591. doi: 10.1007/s10620-018-5020-9. Epub 2018 Mar 21.
5
Change in erythrocyte mean corpuscular volume during combination therapy with azathioprine and infliximab is associated with mucosal healing: a post hoc analysis from SONIC.硫唑嘌呤与英夫利昔单抗联合治疗期间红细胞平均体积的变化与黏膜愈合相关：来自SONIC研究的事后分析
Inflamm Bowel Dis. 2015 Mar;21(3):606-14. doi: 10.1097/MIB.0000000000000302.
6
Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives.炎症性肠病中的硫嘌呤：新发现与新视角。
J Crohns Colitis. 2018 Apr 27;12(5):610-620. doi: 10.1093/ecco-jcc/jjx181.
7
[A case of a simple ulcer associated with ulcerative colitis that demonstrated a good clinical response to infliximab].[一例与溃疡性结肠炎相关的单纯溃疡病例，对英夫利昔单抗表现出良好的临床反应]
Nihon Shokakibyo Gakkai Zasshi. 2015;112(9):1682-8. doi: 10.11405/nisshoshi.112.1682.
8
Azathioprine-Induced Sweet Syndrome Treated With Infliximab.英夫利昔单抗治疗硫唑嘌呤诱发的Sweet综合征
Am J Ther. 2019 Sep/Oct;26(5):e616-e617. doi: 10.1097/MJT.0000000000000820.
9
Is It Useful to Monitor Thiopurine Metabolites in Pediatric Patients with Crohn's Disease on Combination Therapy? A Multicenter Prospective Observational Study.在联合治疗的克罗恩病儿科患者中监测硫嘌呤代谢物是否有用？一项多中心前瞻性观察研究。
Paediatr Drugs. 2021 Mar;23(2):183-194. doi: 10.1007/s40272-021-00439-1. Epub 2021 Mar 11.
10
Infliximab and azathioprine: bridge or parachute?英夫利昔单抗和硫唑嘌呤：桥梁还是降落伞？
Gastroenterology. 2006 Apr;130(4):1354-7. doi: 10.1053/j.gastro.2006.02.038.
引用本文的文献
1
Uncovering novel therapeutic clues for hypercoagulable active ulcerative colitis: novel findings from old data.揭示高凝性活动性溃疡性结肠炎的新治疗线索：旧数据中的新发现
Gastroenterol Rep (Oxf). 2024 Dec 28;12:goae105. doi: 10.1093/gastro/goae105. eCollection 2024.
2
Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-α.源于药代动力学的不良预后因素可预测接受抗肿瘤坏死因子-α治疗的炎症性肠病患者的结局。
Front Immunol. 2024 Jan 23;15:1342477. doi: 10.3389/fimmu.2024.1342477. eCollection 2024.
3
Older Adults With Inflammatory Bowel Disease Are at Higher Risk of Developing Antibodies to Infliximab.患有炎症性肠病的老年人产生英夫利昔单抗抗体的风险更高。
Inflamm Bowel Dis. 2024 Dec 5;30(12):2509-2511. doi: 10.1093/ibd/izad305.
4
Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases.治疗药物监测中的挑战：优化炎症性肠病和其他免疫介导的炎症性疾病患者的生物治疗。
Ther Drug Monit. 2023 Oct 1;45(5):579-590. doi: 10.1097/FTD.0000000000001095. Epub 2023 Apr 3.
5
Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial).使用药代动力学仪表板主动优化英夫利昔单抗与克罗恩病患者标准治疗的比较：一项随机、对照、多中心、开放标签研究（OPTIMIZE 试验）的研究方案。
BMJ Open. 2022 Apr 1;12(4):e057656. doi: 10.1136/bmjopen-2021-057656.
本文引用的文献
1
Effect of IBD medications on COVID-19 outcomes: results from an international registry.IBD 药物对 COVID-19 结局的影响：来自国际注册研究的结果。
Gut. 2021 Apr;70(4):725-732. doi: 10.1136/gutjnl-2020-322539. Epub 2020 Oct 20.
2
Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease.NUDT15 基因变异与炎症性肠病患者硫嘌呤诱导的骨髓抑制相关。
JAMA. 2019 Feb 26;321(8):773-785. doi: 10.1001/jama.2019.0709.
3
Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis.英夫利昔单抗联合硫唑嘌呤治疗可改善英夫利昔单抗的药代动力学特征和疗效：一项事后分析。
Clin Gastroenterol Hepatol. 2019 Jul;17(8):1525-1532.e1. doi: 10.1016/j.cgh.2018.09.033. Epub 2018 Sep 26.
4
Proactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD.英夫利昔单抗单药治疗主动优化与联合治疗在 IBD 中同样有效。
Inflamm Bowel Dis. 2019 Jan 1;25(1):134-141. doi: 10.1093/ibd/izy203.
5
Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease.硫嘌呤类药物或肿瘤坏死因子拮抗剂单独使用或联合使用与炎症性肠病患者淋巴瘤风险之间的关联
JAMA. 2017 Nov 7;318(17):1679-1686. doi: 10.1001/jama.2017.16071.
6
American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease.美国胃肠病学会关于炎症性肠病治疗药物监测的学会指南。
Gastroenterology. 2017 Sep;153(3):827-834. doi: 10.1053/j.gastro.2017.07.032. Epub 2017 Aug 3.
7
Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy.在接受联合治疗的炎症性肠病患者中，6-硫代鸟嘌呤核苷酸的浓度与英夫利昔单抗的谷浓度相关。
Clin Gastroenterol Hepatol. 2015 Jun;13(6):1118-24.e3. doi: 10.1016/j.cgh.2014.12.026. Epub 2015 Jan 3.
8
Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis.针对慢性免疫介导炎症性疾病的肿瘤坏死因子单克隆抗体的免疫原性：系统评价和荟萃分析。
JAMA Intern Med. 2013 Aug 12;173(15):1416-28. doi: 10.1001/jamainternmed.2013.7430.
9
Infliximab, azathioprine, or combination therapy for Crohn's disease.英夫利昔单抗、硫唑嘌呤或联合治疗克罗恩病。
N Engl J Med. 2010 Apr 15;362(15):1383-95. doi: 10.1056/NEJMoa0904492.
Zotero 插件